[go: up one dir, main page]

WO2014115169A3 - Dispersion solide de crizotinib - Google Patents

Dispersion solide de crizotinib Download PDF

Info

Publication number
WO2014115169A3
WO2014115169A3 PCT/IN2014/000052 IN2014000052W WO2014115169A3 WO 2014115169 A3 WO2014115169 A3 WO 2014115169A3 IN 2014000052 W IN2014000052 W IN 2014000052W WO 2014115169 A3 WO2014115169 A3 WO 2014115169A3
Authority
WO
WIPO (PCT)
Prior art keywords
crizotinib
present
solid dispersion
preparation
provides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IN2014/000052
Other languages
English (en)
Other versions
WO2014115169A2 (fr
Inventor
Bandi Parthasaradhi Reddy
Kura Rathnakar Reddy
Dasari Muralidhara Reddy
Thungathurthy Srinivasa Rao
Bandi Vamsi Krishna
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hetero Research Foundation
Original Assignee
Hetero Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hetero Research Foundation filed Critical Hetero Research Foundation
Publication of WO2014115169A2 publication Critical patent/WO2014115169A2/fr
Anticipated expiration legal-status Critical
Publication of WO2014115169A3 publication Critical patent/WO2014115169A3/fr
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La présente invention concerne un composé de sel d'oxalate de crizotinib, son procédé de préparation et des compositions pharmaceutiques le comprenant. La présente invention concerne également un nouveau procédé pour la préparation de crizotinib à l'aide d'un nouvel intermédiaire. La présente invention concerne en outre un procédé pour la purification de crizotinib. La présente invention concerne en outre une nouvelle dispersion solide amorphe de crizotinib en combinaison avec un support pharmaceutiquement acceptable, son procédé de préparation et des compositions pharmaceutiques la comprenant.
PCT/IN2014/000052 2013-01-24 2014-01-23 Dispersion solide de crizotinib Ceased WO2014115169A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN329/CHE/2013 2013-01-24
IN329CH2013 2013-01-24

Publications (2)

Publication Number Publication Date
WO2014115169A2 WO2014115169A2 (fr) 2014-07-31
WO2014115169A3 true WO2014115169A3 (fr) 2016-02-25

Family

ID=51228161

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2014/000052 Ceased WO2014115169A2 (fr) 2013-01-24 2014-01-23 Dispersion solide de crizotinib

Country Status (1)

Country Link
WO (1) WO2014115169A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115919866A (zh) * 2022-12-07 2023-04-07 深圳海王医药科技研究院有限公司 特泊替尼固体分散体及其制备方法
CN115887406B (zh) * 2022-12-24 2024-02-13 山东理工职业学院 一种克唑替尼胶囊的制备方法
CN116688139B (zh) * 2023-06-25 2024-03-29 深圳市新阳唯康科技有限公司 一种克唑替尼药物组合物及其制备方法和应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080300273A1 (en) * 2005-12-05 2008-12-04 Pfizer Inc. Method of Treating Abnormal Cell Growth
US7858643B2 (en) * 2004-08-26 2010-12-28 Agouron Pharmaceuticals, Inc. Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors
US8217057B2 (en) * 2005-12-05 2012-07-10 Pfizer Inc. Polymorphs of a c-MET/HGFR inhibitor

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7858643B2 (en) * 2004-08-26 2010-12-28 Agouron Pharmaceuticals, Inc. Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors
US20080300273A1 (en) * 2005-12-05 2008-12-04 Pfizer Inc. Method of Treating Abnormal Cell Growth
US8217057B2 (en) * 2005-12-05 2012-07-10 Pfizer Inc. Polymorphs of a c-MET/HGFR inhibitor

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KONING ET AL.: "Fit-for-Purpose Development of the Enabling Route to Crizotinib (PF-02341066", ORG. PROCESS RES. DEV., vol. 15, no. 5, 2011, pages 1018 - 1026, XP055078841, DOI: doi:10.1021/op200131n *

Also Published As

Publication number Publication date
WO2014115169A2 (fr) 2014-07-31

Similar Documents

Publication Publication Date Title
CA2894892A1 (fr) Derives d'acide boronique et leurs utilisations therapeutiques
IL233154A (en) Compounds, pharmaceuticals containing them and their uses
EP3040072A4 (fr) Composition pharmaceutique ayant un composé pyrimidine comme principe actif
MX2013012542A (es) Compuestos de amida y aplicacion farmaceutica para el mismo.
CA2830549C (fr) Procedes et compositions pour la preparation de noribogaine a partir de voacangine
HK1206028A1 (en) Phenicol antibacterials
MX2021011906A (es) Composiciones de liberacion retardada de linaclotida.
WO2014076712A3 (fr) Dispersion solide de chlorhydrate de lurasidone
WO2012068441A3 (fr) Sels d'intedanib et leurs formes à l'état solide
WO2015104658A3 (fr) Dispersion solide amorphe de dapagliflozine et procédé pour la préparation de dapagliflozine amorphe
WO2014153495A9 (fr) Nouveaux inhibiteurs de stats3
IL241038B (en) A new salt of abacinostat, a related crystalline form, a method for their preparation and pharmaceutical preparations containing them
WO2015092810A3 (fr) Forme amorphe d'idélalisib
MX363530B (es) Compuesto de benzoxaborol tricíclico, método de preparación y uso del mismo.
WO2015002755A3 (fr) Composés pour le traitement du paludisme
HK1212978A1 (zh) 芥子酸的新型衍生物
WO2014115169A3 (fr) Dispersion solide de crizotinib
WO2014009970A3 (fr) Dispersion solide de linagliptine
WO2014197536A3 (fr) Nouvelles bêta lactames en tant que modulateurs d'absorption du glutamate et leurs procédés d'utilisation
IN2012CH01309A (fr)
WO2014105777A8 (fr) Sel de dichlohydrate de cobicistat
AU2013338098A8 (en) Solid salt form of alpha-6-mPEG6-O-hydroxycodone as opioid agonists and uses thereof
WO2016020408A3 (fr) Composés pour prévenir l'ototoxicité
WO2014195977A3 (fr) Nouveaux polymorphes de vismodegib
WO2015044434A3 (fr) Fluoro-9-méthyl-β-carboline

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14743833

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 14743833

Country of ref document: EP

Kind code of ref document: A2